• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雄激素受体在人类健康中的作用:一个潜在的治疗靶点。

Androgen receptor in human health: a potential therapeutic target.

机构信息

Molecular Chemoprevention and Therapeutics, The Hormel Institute, University of Minnesota, Austin, MN 55912, USA.

出版信息

Curr Drug Targets. 2012 Dec;13(14):1907-16. doi: 10.2174/138945012804545579.

DOI:10.2174/138945012804545579
PMID:23140299
Abstract

Androgen is a key for the activation of Androgen Receptor (AR) in most of the disease conditions, however androgen-independent activation of AR is also found in aggressive type human malignancies. An intense search for the inhibitors of AR is underway to cure AR-dependent diseases. In addition to targeting various components of AR signaling pathway, compounds which directly target AR are under preclinical and clinical investigation. Various In vitro and preclinical animal studies suggest that different natural compounds have potential to act against AR. Some natural compounds have been found to be pharmacologically effective against AR irrespective of varying routs of administration viz; oral, intra-peritoneal and intravenous. This mini-review summarizes the studies conducted with different natural agents in determining their pharmacological utility against AR signaling.

摘要

雄激素是大多数疾病条件下激活雄激素受体 (AR) 的关键,但在侵袭性人类恶性肿瘤中也发现了雄激素非依赖性的 AR 激活。目前正在积极寻找 AR 的抑制剂,以治疗 AR 依赖性疾病。除了针对 AR 信号通路的各种成分外,直接针对 AR 的化合物也正在进行临床前和临床研究。各种体外和临床前动物研究表明,不同的天然化合物具有针对 AR 的潜力。一些天然化合物已被发现具有对抗 AR 的药理作用,而不管给药途径如何,例如口服、腹腔内和静脉内。本综述总结了使用不同天然药物进行的研究,以确定它们在对抗 AR 信号方面的药理作用。

相似文献

1
Androgen receptor in human health: a potential therapeutic target.雄激素受体在人类健康中的作用:一个潜在的治疗靶点。
Curr Drug Targets. 2012 Dec;13(14):1907-16. doi: 10.2174/138945012804545579.
2
Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.特异地针对雄激素依赖性和非依赖性 AR 信号在前列腺癌中的作用,以克服雄激素抵抗。
FASEB J. 2020 Sep;34(9):11511-11528. doi: 10.1096/fj.201903167R. Epub 2020 Jul 26.
3
Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.新型雄激素合成抑制剂对激素依赖性前列腺癌的抗雄激素作用
Cancer Res. 2000 Dec 1;60(23):6630-40.
4
Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.前列腺癌激素治疗的关键靶点。第1部分:雄激素受体和类固醇生成途径。
BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24.
5
Androgen action and metabolism in prostate cancer.雄激素在前列腺癌中的作用及其代谢。
Mol Cell Endocrinol. 2012 Sep 5;360(1-2):3-13. doi: 10.1016/j.mce.2011.09.046. Epub 2012 Mar 20.
6
Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.针对前列腺癌雄激素信号轴和雄激素受体的研究性治疗方法-最新进展和未来方向。
Expert Opin Investig Drugs. 2018 Oct;27(10):811-822. doi: 10.1080/13543784.2018.1513490. Epub 2018 Aug 31.
7
Advances in androgen receptor targeted therapy for prostate cancer.雄激素受体靶向治疗前列腺癌的研究进展。
J Cell Physiol. 2014 Mar;229(3):271-6. doi: 10.1002/jcp.24456.
8
Androgen receptor as a therapeutic target.雄激素受体作为治疗靶点。
Adv Drug Deliv Rev. 2010 Oct 30;62(13):1277-84. doi: 10.1016/j.addr.2010.08.002. Epub 2010 Aug 12.
9
Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.3,3'-二吲哚甲烷对雄激素受体的下调作用有助于抑制激素敏感的LNCaP和不敏感的C4-2B前列腺癌细胞的增殖并诱导其凋亡。
Cancer Res. 2006 Oct 15;66(20):10064-72. doi: 10.1158/0008-5472.CAN-06-2011.
10
Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.雄激素上调前列腺癌细胞中的胰岛素样生长因子-I受体。
Cancer Res. 2005 Mar 1;65(5):1849-57. doi: 10.1158/0008-5472.CAN-04-1837.

引用本文的文献

1
Efficacy and safety of Tanshinone capsule in Acne vulgaris: a systematic review and meta-analysis.丹参酮胶囊治疗寻常痤疮的疗效与安全性:一项系统评价和Meta分析
Front Pharmacol. 2025 Mar 31;16:1520039. doi: 10.3389/fphar.2025.1520039. eCollection 2025.
2
Synergistic Strategies for Castration-Resistant Prostate Cancer: Targeting AR-V7, Exploring Natural Compounds, and Optimizing FDA-Approved Therapies.去势抵抗性前列腺癌的协同策略:靶向AR-V7、探索天然化合物以及优化FDA批准的疗法。
Cancers (Basel). 2024 Aug 6;16(16):2777. doi: 10.3390/cancers16162777.
3
Molecular Insight into Prostate Cancer: Preventive Role of Selective Bioactive Molecules.
前列腺癌的分子洞察:选择性生物活性分子的预防作用
Life (Basel). 2023 Sep 27;13(10):1976. doi: 10.3390/life13101976.
4
Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells.通过联合抑制MDM2和MDMX激活前列腺癌细胞中的p53并使雄激素受体不稳定
Oncotarget. 2017 Dec 15;9(5):6270-6281. doi: 10.18632/oncotarget.23569. eCollection 2018 Jan 19.
5
Integration of VDR genome wide binding and GWAS genetic variation data reveals co-occurrence of VDR and NF-κB binding that is linked to immune phenotypes.维生素D受体(VDR)全基因组结合与全基因组关联研究(GWAS)遗传变异数据的整合揭示了VDR与核因子κB(NF-κB)结合的共现,这与免疫表型相关。
BMC Genomics. 2017 Feb 6;18(1):132. doi: 10.1186/s12864-017-3481-4.
6
Identification of androgen receptor splice variant transcripts in breast cancer cell lines and human tissues.鉴定乳腺癌细胞系和人体组织中的雄激素受体剪接变体转录本。
Horm Cancer. 2014 Apr;5(2):61-71. doi: 10.1007/s12672-014-0171-4. Epub 2014 Feb 26.
7
BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling.BMI1 多梳组蛋白作为肿瘤细胞生长和死亡的主开关:调节 TCF4-转录因子诱导的 BCL2 信号通路。
PLoS One. 2013 May 6;8(5):e60664. doi: 10.1371/journal.pone.0060664. Print 2013.